Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study [Yahoo! Finance]
Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update [Yahoo! Finance]
Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update